Rapid assessment of antigenic characterisation capability and capacity for SARS-CoV-2 viruses in EU/EEA laboratories

Technical report
Cite:

European Centre for Disease Prevention and Control. Rapid assessment of antigenic characterisation capability and capacity for SARS-CoV-2 viruses in EU/EEA laboratories – 20 December 2021. Stockholm: ECDC; 2021.

This is the fifth survey assessing the capacity and needs of laboratories in the EU/EEA, with a focus on antigenic characterisation capability and capacity for SARS-CoV-2 viruses.

Executive summary

Key messages

  • EU/EEA countries and Switzerland have substantial capability and capacity in antigenic characterisation of SARS-CoV-2 viruses across the region.
  • Multiple methods for antigenic characterisation of SARS-CoV-2 have been implemented in EU/EEA laboratories.
  • Additional EU/EEA countries are in the process of adding antigenic characterisation to their laboratory methods.
  • The main bottlenecks in this area are access to method protocols, reagents, BSL3 facilities and training for laboratory personnel.
  • ECDC is supporting EU/EEA countries through central laboratory testing activities, as well as information and protocol sharing and upcoming training activities.